Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Ibere Pharmaceuticals (IBERU)

Sector - SPAC

Price chart

-100%
Return from IPO

Last SPACs News

IPO Profile

About company

They are a blank check company. Their sponsor is PIPV Capital LLC, a Delaware limited liability company. Their sponsor is led by Osagie Imasogie, Lisa Gray and Zoltan Kerekes, who are healthcare industry veterans who have worked together for the past two decades and initially managed GlaxoSmithKline Ventures, the intellectual property venture capital arm of GlaxoSmithKline PLC (LSE: GSK), where they executed approximately 30 transactions from 2000 to 2003. They subsequently formed Phoenix IP Ventures LLC ("PIPV"), which is a healthcare sector-focused private equity manager specializing in acquiring revenue-generating, high quality assets in the pharmaceutical and life sciences industries. PIPV has deployed in excess of $1 billion in institutional funds across diverse therapeutic areas, including dermatology, oncology, central nervous system, and analgesia/pain and over a broad, global scope. PIPV has generated returns exceeding 20%. Their acquisition strategy will leverage their management team’s proprietary network of long-standing relationships and industry contacts as well as inbound opportunities to source a business combination. They intend to identify and acquire one or more pharmaceutical or life science businesses.
Industry
Blank Checks
CEO CFO
Osagie Imasogie Lisa Gray
Employees Founded
0 2020

Contacts

Address: 2005 Market Street, Suite 2030 Philadelphia, Pa 19103, Us

Telephone: (267) 765-3222

Web page: http://phoenixipv.com

IPO information

First Trade Date 2/26/2021
Status Priced
Exchange NYSE
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 10
Shares Revised (MM) 12
Expected offer amount (MM) $100
Realized offer amount(MM) $120

Financial Data (last reporting year)

Market Cap (MM) $145
Revenues (MM) $0
Net Income (Loss) (MM) $0

Voting

What do you think will happen with the IBERU share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Underwriters
Raymond James
CO-Managers
-